Nepicastat + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Posttraumatic Stress Disorder

Conditions

Posttraumatic Stress Disorder

Trial Timeline

Jul 1, 2009 → Aug 30, 2012

NCT ID

NCT00659230

About Nepicastat + Placebo

Nepicastat + Placebo is a phase 2 stage product being developed by Johnson & Johnson for Posttraumatic Stress Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00659230. Target conditions include Posttraumatic Stress Disorder.

What happened to similar drugs?

3 of 4 similar drugs in Posttraumatic Stress Disorder were approved

Approved (3) Terminated (1) Active (1)

🔄Duloxetine hydrochlorideEli LillyPhase 3

✅Placebo + sertralineJohnson & JohnsonApproved

✅Adjunctive asenapineMerckApproved

✅ZiprasidonePfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00659230	Phase 2	Completed	Jul 1, 2009	Aug 30, 2012	Posttraumatic Stress Disorder

Competing Products

8 competing products in Posttraumatic Stress Disorder

See all competitors

Product	Company	Stage	Hype Score
Duloxetine hydrochloride	Eli Lilly	Phase 3	36
Placebo + sertraline	Johnson & Johnson	Approved	35
Adjunctive asenapine	Merck	Approved	43
sertraline (Zoloft)	Pfizer	Pre-clinical	26
Ziprasidone	Pfizer	Approved	43
Methylphenidate Hydrochloride 20 mg + Placebo Capsule + Galantamine 12 mg	Brain Biotech	Phase 2	17
High THC/Low CBD Cannabis + High THC/High CBD Cannabis + Low THC/Low CBD Cannabis	Tilray	Phase 2	29
Riluzole	Brain Biotech	Phase 1	19